GLP-1 receptor agonist therapies remain costly, resource-intensive, and often require specialist oversight
Pennsylvania Student Sustainability Symposium Location: Dickinson College Mackenzie Joan Johnson Farm and Food Education Programs Nurture the Next Generation Date: March 21, 2014 Event: 2014 Pennsylvania Environmental Resource Consortium
A car parked in sunlight in most of the United States will exceed 86 degrees within minutes
Lipo-C includes Methionine, Inositol, and Choline
NICE guidance (NG28) recommends GLP-1 receptor agonists as a treatment option for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated The person has a BMI of 35 kg/m or higher (adjust accordingly for people from particular ethnic groups) and specific psychological or other medical problems associated with obesity The person has a BMI lower than 35 kg/m and insulin would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 receptor agonists may also be considered in combination with insulin therapy in specialist care settings Beyond glycaemic control, specific GLP-1 receptor agonists offer significant cardiovascular benefits
Stick to the recommended serving size for the best long-term value
